Yamo Pharmaceuticals
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
400 Madison Ave Rm 11A, New York City, N...Phone Number
(212) 610-1578Website
www.yamopharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Yamo Pharmaceuticals
Yamo Pharmaceuticals is focused on developing L1-79, an oral therapy aimed at addressing the core social-interaction symptoms of Autism Spectrum Disorder. The company is currently in Phase 2 of its clinical trials and has received FDA Fast Track designation. Their primary clients include individuals affected by autism and healthcare providers seeking effective treatment options. Yamo Pharmaceuticals is dedicated to restoring connection and improving the quality of life for those with autism.Explore more
Yamo Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Yamo Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Yamo Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Yamo Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Yamo Pharmaceuticals
Click to see if Yamo Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Yamo Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Yamo Pharmaceuticals has new funding data
Check out if Yamo Pharmaceuticals is spiking on competitors!
Check if Yamo Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Yamo Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Yamo Pharmaceuticals
Compare insights from companies similar to Yamo Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
2019
KW
Karen Walton-BowenClinical Operations, Biostatistical Analysis & Reporting Head
Company Profile Activity
Activity Insights
Yamo Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Yamo Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Yamo Pharmaceuticals.
Yamo Pharmaceuticals financials insights
Gather financial insights about Yamo Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$89K
Yamo Pharmaceuticals Tech Stack
A closer look at the technologies used by Yamo Pharmaceuticals
Yamo Pharmaceuticals News & Media
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
Yamo Pharmaceuticals announces positive topline results from Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorderYamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum Disorder
New York, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for the core symptoms of the autism spectrum disorder (ASD), announced that The Autism Impact Fund has made a capital investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD. L1-79, the company’s lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated inYamo Pharmaceuticals Presents Results from Phase 2 Study of L1-79 in Adolescents and Young Adult Males with Autism Spectrum Disorder at INSAR 2019
New York , May 14, 2019 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced the presentation of results from a Phase 2 study with L1-79 in the treatment of ASD. A poster entitled “An Open Label and Double Blind Randomized Placebo Controlled Pilot Study of L1-79 [D,L Alpha-Methyl-Para-Tyrosine (DL-AMPT)] for the Treatment of the Core Symptoms of Autism Spectrum Disorder (ASD) inFDA Grants Fast Track Designation for Yamo Pharmaceutical’s L1-79 in Autism Spectrum Disorder
New York, May 14, 2018 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, LLC, a clinical stage pharmaceutical company developing a novel therapy for autism spectrum disorder (ASD), announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug L1-79, a tyrosine hydroxylase inhibitor intended to mitigate the socialization and communication symptoms in individuals with ASD. L1-79 has shown the potential to address an unmet medical need for th
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Yamo Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Yamo Pharmaceuticals is focused on developing L1-79, an oral therapy aimed at addressing the core social-interaction symptoms of Autism Spectrum Disorder. The company is currently in Phase 2 of its clinical trials and has received FDA Fast Track designation. Their primary clients include individuals affected by autism and healthcare providers seeki... Read More
